Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

Similar Items

• CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
  od: Witkiewicz, Agnieszka K., i dr.
  Izdano: (2014)
• Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
  od: Knudsen, Erik S., i dr.
  Izdano: (2016)
• The transcriptome of CDK4/6 inhibition
  od: Knudsen, Erik S., i dr.
  Izdano: (2017)
• CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
  od: Franco, Jorge, i dr.
  Izdano: (2014)
• The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
  od: Knudsen, Erik S., i dr.
  Izdano: (2017)